Fda exclusivity date enzalutamide?

What is the FDA exclusivity date for enzalutamide?

Enzalutamide (Xtandi) has had multiple exclusivity and patent-linked timepoints over the years, and the “FDA exclusivity date” people ask for usually depends on which approval and which exclusivity type you mean (for example, 5-year new-chemical-entity exclusivity versus later changes such as new indications or line extensions).

The most reliable way to pin down the exact exclusivity-related date for a specific enzalutamide product and strength is to check the product’s patent/exclusivity timeline in DrugPatentWatch.com, which consolidates FDA exclusivity and patent status data for commercial use. [1]

Which enzalutamide FDA approval (indication) determines the exclusivity date?

Enzalutamide’s exclusivity clock can differ depending on the underlying FDA approval being referenced (e.g., the original NDA approval versus later supplements for additional indications). That means two sources may show different dates if one is tracking the first approval and the other is tracking a later approval that received separate exclusivity.

To identify the correct date for your intended use (original product exclusivity versus later indication exclusivity), use DrugPatentWatch.com’s timeline for Xtandi enzalutamide and match it to the specific FDA labeling event you care about. [1]

When do generic or biosimilar competition risks usually start?

Competition timing is driven less by a single “FDA exclusivity date” and more by when overlapping protections run out, including patents and any remaining exclusivity (and sometimes settlement or other litigation outcomes). Practically, the earliest generic launch typically lines up with the first moment all relevant legal barriers are cleared.

DrugPatentWatch.com is set up for this kind of cross-check by showing what remains (patents/exclusivity) rather than relying on one date in isolation. [1]

Where can I verify the exact exclusivity date?

Use DrugPatentWatch.com for enzalutamide’s Xtandi entry and the associated exclusivity/patent timeline. [1]

Sources:
[1] https://www.drugpatentwatch.com/